- Document Number:
20230395255
- Appl. No:
18/250206
- Application Filed:
October 22, 2021
- نبذة مختصرة :
Disclosed herein are methods for identifying the neuronal and neurodegenerative phenotypes affected by and identified in Alzheimer's Disease, characterized as Alzheimer's Disease subtypes, methods for identifying drugs effective for treating Alzheimer's Disease subtypes, and drugs useful in treating Alzheimer's Disease subtypes.
- Assignees:
Icahn School of Medicine at Mount Sinai (New York, NY, US)
- Claim:
1. A method for treating Alzheimer's Disease in a patient in need thereof, the method comprising detecting markers associated with at least one Alzheimer's Disease (AD) subtype in a biological sample from said patient, normalizing said marker levels, using a trained machine learning technique to provide a score for the AD subtype of said patient, comparing said score with a predetermined reference standard, determining said AD subtype, and providing a treatment for said AD subtype.
- Claim:
2. The method of claim 1, wherein said detecting markers is a Weighted Sample Correlation Network Analysis (WSCNA).
- Claim:
3. The method of claim 2, wherein said detecting identifies polynucleotide markers, polypeptide markers, or both.
- Claim:
4. The method of claim 3, wherein said polynucleotide markers are selected from the group consisting of: polynucleotide length, epigenetic markers, methylation levels, nucleotide sequence, copy number, single nucleotide polymorphisms, sequence expression levels, RNA expression, RNA stability, and sequence transpositions or translocations.
- Claim:
5. The method of claim 3, wherein said detecting identifies polypeptides, epitopes, or fragments.
- Claim:
6. The method of claim 2, wherein said biological sample is selected from the group consisting of: blood, cerebrospinal fluid, lymphatic tissue, cells, epithelial tissue, and adipose tissue.
- Claim:
7. The method of claim 2, wherein the at least one Alzheimer's Disease subtype is selected from the group consisting of: AD subtype A, AD subtype B1, AD subtype B2, AD subtype C1, and AD subtype C2.
- Claim:
8. The method of claim 2, comprising providing a therapeutically effective amount of a drug selected from the group consisting of: thioproperazine; nalbuphine; gabexate; mesoridazine; menadione; carbamazepine; diphenidol; epirizole; timolol; mestranol; naphazoline; hesperidin; ethisterone; amlodipine; amsacrine; febuxostat; famciclovir; ezetimibe; carbetocin; orphenadrine; hyoscyamine; amiodarone.hcl; erythromycin-ethylsuccinate; meclizine; dobutamine; phenazopyridine; spironolactone; meclofenamic-acid; parachorophenol; bemegride; ketorolac; and brinzolamide.
- Claim:
9. The method of claim 1, wherein the trained machine learning technique is selected from the group consisting of: Random Forest, hierarchical clustering, k-means clustering, MEGENA, Bayesian causal network, CNVnator, Pindel, MetaSV, Delly2, Quasipoisson regression, AdaBoost, logistic regression, decision tree, nearest neighbors (KNN), support vector machines (SVM), naïve Bayes, multi-layer perceptron, and Ensemble.
- Claim:
10. A computer-implemented method to predict an AD subtype of a subject, the method comprising: obtaining data concerning specific characteristics of a biological sample collected from a subject; providing said data as input to a trained machine learning technique, wherein the technique determines the AD subtype based on the data; wherein the AD subtype is any one of: AD subtype A, AD subtype B1, AD subtype B2, AD subtype C1, or AD subtype C2; and obtaining, from the machine learning technique, the predicted AD subtype.
- Claim:
11. The method of claim 10, wherein said machine learning technique is a Weighted Sample Correlation Network Analysis (WSCNA).
- Claim:
12. The method of claim 10, wherein said biological sample is selected from the group consisting of: blood, cerebrospinal fluid, lymphatic tissue, cells, epithelial tissue, and adipose tissue.
- Claim:
13. The method of claim 10, wherein said data comprises information concerning polynucleotide markers, polypeptide markers, or both.
- Claim:
14. The method of claim 13, wherein said polynucleotide markers are selected from the group consisting of: sequence length, epigenetic markers, methylation levels, sequence code, copy number, single nucleotide polymorphisms, sequence expression levels, RNA expression, RNA stability, and sequence transpositions or translocations.
- Claim:
15. The method of claim 13, wherein said data comprises information concerning polypeptides, epitopes, or fragments.
- Claim:
16. The method of claim 10, wherein the trained machine learning technique is selected from the group consisting of: Random Forest, hierarchical clustering, k-means clustering, MEGENA, Bayesian causal network, CNVnator, Pindel, MetaSV, Delly2, Quasipoisson regression, AdaBoost, logistic regression, decision tree, nearest neighbors (KNN), support vector machines (SVM), naïve Bayes, multi-layer perceptron, and Ensemble
- Claim:
17. A method for treating Alzheimer's in a subject in need thereof, the method comprising: receiving the AD subtype of the subject, which has been obtained using the method of claim 11 and administering a therapeutically effective amount of drug for targeting the obtained AD subtype.
- Claim:
18. The method of claim 17, comprising administering a therapeutically effective amount of a drug selected from the group consisting of: thioproperazine; nalbuphine; gabexate; mesoridazine; menadione; carbamazepine; diphenidol; epirizole; timolol; mestranol; naphazoline; hesperidin; ethisterone; amlodipine; amsacrine; febuxostat; famciclovir; ezetimibe; carbetocin; orphenadrine; hyoscyamine; amiodarone.hcl; erythromycin-ethylsuccinate; meclizine; dobutamine; phenazopyridine; spironolactone; meclofenamic-acid; parachorophenol; bemegride; ketorolac; and brinzolamide.
- Claim:
19. The method of claim 2, further comprising using computer implemented method for identifying candidate compounds for use in treating an Alzheimer's Disease subtype, the method comprising: obtaining data of drug induced signatures for candidate compounds and Alzheimer's Disease subtype signatures; providing the data as input to a trained machine learning model, wherein the model is EDMURA; and obtaining from the model, the drug associated with an Alzheimer's Disease subtype.
- Claim:
20. The method of claim 11, further comprising using computer implemented method for identifying candidate compounds for use in treating an Alzheimer's Disease subtype, the method comprising: obtaining data of drug induced signatures for candidate compounds and Alzheimer's Disease subtype signatures; providing the data as input to a trained machine learning model, wherein the model is EDMURA; and obtaining from the model, the drug associated with an Alzheimer's Disease subtype.
- Current International Class:
16; 16; 16; 16
- الرقم المعرف:
edspap.20230395255
Processing Request
No Comments.